menu search

kymera therapeutics, inc. (kymr) q3 2023 earnings call transcript

kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET C...

November 4, 2023, 1:10 pm

kymera therapeutics, inc. (kymr) loses -33.08% in 4 weeks, here's why a trend reversal may be around the corner

kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressur...

October 19, 2023, 11:21 am

kymera therapeutics, inc. (kymr) loses -35.95% in 4 weeks, here's why a trend reversal may be around the corner

The heavy selling pressure might have exhausted for kymera Therapeutics, Inc. (KYMR) as it is technical...

October 18, 2023, 11:19 am

kymera therapeutics, inc. (kymr) soars 14.3%: is further upside left in the stock?

kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being hig...

October 4, 2023, 7:31 am

Why shares of kymera therapeutics jumped on tuesday

kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead t...

October 3, 2023, 4:48 pm

kymera therapeutics - need more developments before making this a buy

kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a...

August 9, 2023, 4:21 pm

Perella weinberg partners (pwp) q2 2023 earnings call transcript

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Fo...

August 6, 2023, 2:55 am

kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associ...

June 14, 2023, 6:30 am

kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...

June 9, 2023, 10:00 pm

kymera: more data needed

kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety ...

May 14, 2023, 9:14 am

kymera therapeutics, inc. (kymr) q1 2023 earnings call transcript

kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company...

May 6, 2023, 6:35 pm

kymera therapeutics to report first quarter 2023 financial results on may 4

WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinic...

April 11, 2023, 7:00 am

kymera therapeutics, inc. (kymr) q4 2022 earnings call transcript

kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET ...

February 25, 2023, 2:43 pm

kymera therapeutics, inc. (kymr) reports q4 loss, misses revenue estimates

kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respect...

February 23, 2023, 9:47 am

kymera: data derisks platform, but i will wait for more

kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did ...

January 23, 2023, 6:58 pm

All you need to know about kymera therapeutics, inc. (kymr) rating upgrade to buy

kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis...

January 9, 2023, 1:33 pm

kymera (kymr) up on positive data from phase i study on kt-474

kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradeniti...

December 15, 2022, 12:02 pm

Why is kymera therapeutics (kymr) stock up 20% today?

What's trending in the pharmaceutical sector today? In a fresh press release, kymera Therapeutics (NASD...

December 14, 2022, 11:08 am

Why small biotech kymera just snagged sanofi's interest and surged 28%

kymera unveiled promising results for its skin-disease treatment on Wednesday, snagging interest from S...

December 14, 2022, 9:58 am

kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm


Search within

Pages Search Results: